Please join Repare Therapeutics in welcoming Dr. Steven H. Stein to our Board of Directors, effective June 17, 2024. Dr. Stein currently serves as the Chief Medical Officer of Incyte Corporation, a position he has held since March 2015. Prior to joining Incyte, Dr. Stein has held leadership positions at Novartis Oncology, GlaxoSmithKline, and Kura Oncology. He has authored more than 100 scientific papers and presentations and is an Adjunct Assistant Professor in the University of Pennsylvania School of Medicine.
Repare Therapeutics’ Post
More Relevant Posts
-
Life Sciences consulting leader with 20+ years of experience; President of BioKatalyst, a non-profit biopharma executives association
See our latest Oncology Pulse! (Ironman vs. Superman?) Meet the Bluestar oncology team at ASCO!
ADCs and radiopharmaceuticals have re-emerged as modalities of high interest in oncology licensing and acquisition – will they be the next wave of breakthroughs or represent a flight to safety in light of the challenges of finding the next hot target and the IRA? Here's a link to our latest Oncology Pulse: https://lnkd.in/gJ4xUFUB Also, ASCO24 is one week away, and abstracts drop today. Our team is looking forward to sifting through the data to understand the implications. We hope to see you in Chicago!
-
Dr. Roy Baynes of Eikon Therapeutics joined us to discuss his process of developing pembrolizumab, also known as Keytruda. Applying his experience as CMO and Head of Development at Merck, he explains what it takes to successfully develop an oncology therapeutic. Read the article here: https://lnkd.in/eCwvmyvV! #ClinicalTrials #DrugDevelopment #Keytruda
-
-
The antibody–drug conjugate (ADC) landscape is rapidly evolving and has become a significant therapeutic modality in oncology. The publication offers a nice overview of the ADC landscape. https://lnkd.in/eSGNKSEB
The antibody–drug conjugate landscape
nature.com
-
Considering the Totality of Efficacy and Safety Data to Aide Registrational Trial Designs: Stacy Shord, PharmD, Jin Y. Jin, PhD, and Scott Van Wart, PhD, will address this topic in a session at the FDA-AACR public workshop on Optimizing Dosages for Oncology Drug Products (Feb 15-16). Learn more: https://bit.ly/3OJgqw1 #AACRSciencePolicy
-
-
Trust the experts who have propelled over 500 oncology projects in 2021. Discover how Certara's biosimulation and regulatory strategy expertise can accelerate your path to success for your oncology drug program. Learn more: https://ow.ly/R73U50P9XTG
Accelerating Oncology Drug Development with Biosimulation and Regulatory Strategy
https://www.certara.com
-
Medical Oncologist/Physician-Scientist @ Vanderbilt University Medical Center & Nashville VA Hospital
Want to learn more about RNAseq as a predictive biomarker in oncology trials, especially our #OPTICRCC trial in #kidneycancer? Great team with Brian Rini, Katy Beckermann, and Anupama Reddy. Register for this webinar: https://lnkd.in/e7EJN83t
Unlocking the power of RNA in drug development
go.tempus.com
-
Antibody drug conjugates (ADCs) “are currently among the most promising drug classes in oncology, with efforts to expand their application for non-oncological indications and in combination therapies.” Read this recent review from authors at CAS, a division of the American Chemical Society, to learn about the current landscape in the ADC field and the challenges that must be overcome to reach their full potential. Read review: https://ow.ly/Wxjg50QfHFT
The Evolving Landscape of Antibody–Drug Conjugates: In Depth Analysis of Recent Research Progress
-
I help researchers tackle their challenging characterizations with the right biophysical tools
If you work with ADCs and like data and numbers, dig in this insightful review from the American Chemical Society for a complete overview of the current landscape and remaining challenges! #antibodydrugconjugates #antibodydiscovery
Antibody drug conjugates (ADCs) “are currently among the most promising drug classes in oncology, with efforts to expand their application for non-oncological indications and in combination therapies.” Read this recent review from authors at CAS, a division of the American Chemical Society, to learn about the current landscape in the ADC field and the challenges that must be overcome to reach their full potential. Read review: https://ow.ly/Wxjg50QfHFT
The Evolving Landscape of Antibody–Drug Conjugates: In Depth Analysis of Recent Research Progress
-
Accelerated approval is an important tool that faciliates earlier patient access to promising therapies by allowing approval based on an early endpoint likely to predict clinical benefit. Confirming the clinical benefit through timely postmarketing confirmatory studies is essential to ensure patients have access to therapies that are safe and effective. Check out the Friends of Cancer Research drug development dashboard to gain data driven insights around the status of Accelerated Approvals and their post-marketing requirements, and endpoints used as the basis for Accelerated and full approvals. Accelerate Approval Dashboard: https://lnkd.in/enknuAgD #oncology #Friends #Patients #Research
Today the FDA Oncologic Drugs Advisory Committee will discuss two #oncology accelerated approvals with overdue confirmatory trials. Our interactive data driven dashboard gives insights into the status of oncology accelerated approvals and their confirmatory trials. Click to access this great public resource: https://lnkd.in/eUwzqFUj
-
-
Read now the latest edition of Pharma insights! In this edition, you'll dive into the complexities of cancer and understand the path forward in oncology drug development! Plus, stay updated with all the information about our upcoming webinar on June 25. Don't miss out! Click here: https://ow.ly/VG2H30sEmt2 #CrodaPharma #PharmaInsights #EmpoweringBiologicsDelivery
-
